Integral Health Asset Management LLC Has $24.06 Million Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD)

Integral Health Asset Management LLC raised its position in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 57.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 550,000 shares of the company's stock after buying an additional 200,000 shares during the period. Revolution Medicines accounts for 2.1% of Integral Health Asset Management LLC's investment portfolio, making the stock its 10th biggest holding. Integral Health Asset Management LLC owned 0.33% of Revolution Medicines worth $24,057,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Revolution Medicines by 14.7% in the fourth quarter. Vanguard Group Inc. now owns 17,096,455 shares of the company's stock valued at $747,799,000 after buying an additional 2,185,082 shares during the period. Farallon Capital Management LLC increased its holdings in Revolution Medicines by 17.1% in the 4th quarter. Farallon Capital Management LLC now owns 13,248,692 shares of the company's stock worth $579,498,000 after acquiring an additional 1,931,000 shares during the last quarter. Janus Henderson Group PLC raised its stake in Revolution Medicines by 54.5% in the 4th quarter. Janus Henderson Group PLC now owns 9,483,999 shares of the company's stock valued at $414,777,000 after acquiring an additional 3,346,755 shares during the period. Baker BROS. Advisors LP raised its stake in Revolution Medicines by 4.9% in the 4th quarter. Baker BROS. Advisors LP now owns 7,936,972 shares of the company's stock valued at $347,163,000 after acquiring an additional 367,882 shares during the period. Finally, FMR LLC lifted its holdings in Revolution Medicines by 14.7% during the fourth quarter. FMR LLC now owns 6,742,083 shares of the company's stock valued at $294,899,000 after purchasing an additional 866,190 shares during the last quarter. Institutional investors own 94.34% of the company's stock.

Wall Street Analysts Forecast Growth

RVMD has been the topic of several research reports. Wedbush reissued an "outperform" rating and issued a $67.00 price target on shares of Revolution Medicines in a research report on Thursday, May 8th. Needham & Company LLC restated a "buy" rating and set a $57.00 target price on shares of Revolution Medicines in a research report on Thursday, May 8th. HC Wainwright reaffirmed a "buy" rating and issued a $72.00 price target (down from $73.00) on shares of Revolution Medicines in a report on Wednesday. Guggenheim decreased their price objective on Revolution Medicines from $87.00 to $80.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Finally, Stifel Nicolaus cut their target price on Revolution Medicines from $78.00 to $64.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $67.08.

Revolution Medicines Price Performance

NASDAQ RVMD traded down $0.04 during trading on Thursday, reaching $39.44. The company's stock had a trading volume of 899,044 shares, compared to its average volume of 1,491,953. The firm has a fifty day moving average of $37.42 and a 200 day moving average of $43.31. Revolution Medicines, Inc. has a one year low of $29.17 and a one year high of $62.40. The stock has a market capitalization of $7.35 billion, a PE ratio of -10.99 and a beta of 1.11.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.01). During the same period in the prior year, the company posted ($0.70) EPS. Research analysts expect that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Jack Anders sold 1,864 shares of Revolution Medicines stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $72,770.56. Following the completion of the sale, the chief financial officer now directly owns 115,006 shares of the company's stock, valued at approximately $4,489,834.24. The trade was a 1.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Margaret A. Horn sold 3,058 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $119,384.32. Following the completion of the transaction, the chief operating officer now directly owns 153,533 shares in the company, valued at approximately $5,993,928.32. This represents a 1.95% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 16,660 shares of company stock valued at $650,406 in the last quarter. Corporate insiders own 8.20% of the company's stock.

Revolution Medicines Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.